MEDP Medpace Holdings Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 98
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: 29
Relative Profitability: Rel. Profitability: 53

EPS in 2025 (TTM): $14.66

Last Report Period Date: Sep 30, 2025

As of November this year, based on Medpace Holdings's latest financial report, the company's current EPS (TTM) is $14.66. Medpace Holdings's earnings per share in 2024 came in at $13.06, marking an increase from $9.2 in 2023. Medpace Holdings's EPS for the quarterly period ending on Sep 30, 2025 was $3.95.

MEDP earnings history

Historical annual and quarterly earnings per share (EPS) data for Medpace Holdings
EPS (TTM)
$14.66
EPS Growth YoY (Quarterly)
27%
EPS (Quarterly)
$3.95
EPS Growth (Quarterly)
25%

The yearly EPS in 2024 was $13.06, an increase of 42% compared to $9.2 recorded in 2023. The quarterly EPS for the period ending Sep 30, 2025, was $3.95, marking a 27% increase compared to the same quarter last year. MEDP's TTM EPS is $14.66 as of September 2025. Medpace Holdings's EPS for 2023 was $9.2, a 21.5% rise from 2022.

MEDP EPS growth

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
27%
EPS growth YoY
42%
EPS growth 3Y avg
37.2%
EPS growth 5Y avg
36.2%

Medpace Holdings has recorded a growth in earnings per share of 27% over the past 12 months (YoY, quarterly). For the last three years, MEDP had an average yearly EPS growth of 37.2%. Medpace Holdings had an average annual EPS growth of 36.2% over the last five years.

MEDP Earnings Waterfall

Breakdown of revenue, profit and net income for Medpace Holdings

MEDP Earnings vs Peers

What are the earnings of MEDP compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
MEDP Medpace Holdings Inc 40.53 42% 37.2% 36.2%
OLMA Olema Pharmaceuticals Inc N/A -2.8% N/A N/A
OMER Omeros Corp N/A -43.6% N/A N/A
VIVS VivoSim Labs Inc. N/A 91.2% N/A N/A
ORIC Oric Pharmaceuticals Inc N/A 6.6% N/A N/A
ORMP Oramed Pharmaceuticals Inc N/A -442.9% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.